MORRIS PLAINS, N.J., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company will be making multiple presentations at 3 upcoming scientific and medical conferences.

At the World ADC San Francisco 2013, scheduled for October 14-17, 2013 in San Francisco, CA, Cynthia L. Sullivan, President and Chief Executive Officer, will present "The Growth Potential for using ADCs: Diverse Cancer Types," including the IMMU-130, IMMU-132 and IMMU-110 program descriptions, during the Commercial Leader's Day session on Monday, October 14, at 9:30 a.m. In addition, Dr. David M. Goldenberg, Chairman, Chief Scientific Officer, and Chief Medical Officer, will report "First Clinical Results of SN-38 ADCs in Solid Tumor Therapy" in the Plenary Session: Early Clinical Trial Results on Wednesday, October 16, at 4:30 p.m.

The Company and its collaborators will present 6 studies at the 26^th Annual Congress of the European Association of Nuclear Medicine to be held in Lyon, France, from October 19-23, 2013. The schedule and meeting places for the presentations, together with the abstract number and session title, are listed below:

• "Preclinical evaluation of Al¹⁸F- and ⁶⁸Ga-labeled GRPR-antagonist for PET imaging of gastrin-releasing peptide receptor expression in prostate cancer" [Abstract No. OP060, Oral Session Title: Radiopharmaceuticals & Radiochemistry & Dosimetry: PET Radiopharmaceuticals, Sunday, October 20, 11:41 a.m. – 11:52 a.m., Room: Rhône 3A/3B]

• "SPECT/fluorescence dual-modality imaging of carcinoembryonic antigen-expressing tumors: a pretargeting study" [Abstract No. OP261, Oral Session Title: Featured - Molecular & Multimodality Imaging: Optical Imaging, Monday, October 21, 12:29 p.m. – 12:40 p.m., Room:  Auditorium Pasteur]

• "A Phase Ιb study of fractionated ⁹⁰Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer after ≥ 2 prior therapies" [Abstract No. OP670, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:00 a.m. – 8:11 a.m., Room:  Gratte-Ciel 1/2/3]

• "Radioimmunotherapy (RAIT) with anti-CD22 ⁹⁰Y-epratuzumab in adults with refractory or relapsed CD22+ ALL: preliminary results of a phase I/II study" [Abstract No. OP675, Oral Session Title: Radionuclide Therapy & Dosimetry: Miscellaneous Therapy, Wednesday, October 23, 8:55 a.m. – 9:06 a.m., Room: Gratte-Ciel 1/2/3]

• "Pharmacokinetics of yttrium-90-labeled epratuzumab in the consolidation radioimmunotherapy of non-Hodgkin's lymphoma" [Abstract No. P400, Poster Session Title: Therapy & Clinical Trials: Radioisotope Therapy - Miscellaneous, Sunday, October 20, 4:00 p.m. – 4:30 p.m., Room:  Poster Exhibition Area]

• "Anti-CEA antibody fragments labeled with [¹⁸F]AlF for PET imaging of CEA-expressing tumors" [Abstract No. PW138, Poster Session Title: Poster Walk 14 - Radiopharmaceuticals & Radiochemistry & Dosimetry: Antibodies & Peptides, Tuesday, October 22, 9:15 a.m. – 9:20 a.m., Room: Poster Exhibition Area]

Finally, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, from October 19-23, 2013, a poster on "Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience" will be presented in Poster Session C: Clinical Trials 3 on Tuesday, October 22, at 12:30 p.m. - 3:00 p.m. in Exhibit Hall C-D.

"These conferences provide the Company with opportunities to describe the progress being made with many of its advanced products involving drug and radionuclide conjugates being studied for the therapy or improved imaging of advanced cancers," commented Cynthia L. Sullivan, President and Chief Executive Officer. She added, "These include our antibody-drug conjugates (ADCs) at two conferences, our novel immunoPET constructs using fluorine-18, and also advances in the therapy of lymphomas and leukemias with our ⁹⁰Y-labeled epratuzumab."

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Our lead product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, we are planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in advanced pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development include 2 antibody-drug conjugates, labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132). We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK™ (DNL™) method with us for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. We believe that our portfolio of intellectual property, which includes approximately 230 active patents in the United States and more than 400 foreign patents, protects our product candidates and technologies. Our strength in intellectual property has resulted in the top-10 ranking in the 2012 IEEE Spectrum Patent Power Scorecards in the Biotechnology and Pharmaceuticals category. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on UCB for the further development of epratuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.